Chinese technology and pharmaceutical companies are strategically leveraging Hong Kong's position as a global financial hub to accelerate their international expansion plans. The city's established infrastructure, regulatory expertise, and cross-border connectivity make it an ideal launchpad for Asian enterprises seeking to penetrate Western markets. State-owned pharmaceutical manufacturers are particularly interested in infrastructure investments, including the Northern Metropolis development project, which promises enhanced logistics and innovation ecosystems to support their growth ambitions.

Summary auto-generated by AI from the original publisher's content. Editorial standards.